Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.

ABSTRACT:

Background

Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor type 5 (CCR5) have been proposed as a pivotal factor in cancer progression since its blockade has been linked with antineoplastic effects on tumor cell proliferation; nevertheless, its role in the chemoresistance of GC has not been elucidated. This study aimed to determine the effects induced by the CCR5 using Maraviroc (MVC), a highly selective CCR5 antagonist, on CDDP-resistant AGS cells (AGS R-CDDP), tumoroids (3D tumor spheroids), and animal models.

Results

The combined CDDP and MVC treat

SUBMITTER: Mora-Lagos B 

PROVIDER: S-EPMC11748569 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature